Logo image of ABBV

ABBVIE INC (ABBV) Stock Fundamental Analysis

NYSE:ABBV - New York Stock Exchange, Inc. - US00287Y1091 - Common Stock - Currency: USD

192.45  -2.55 (-1.31%)

After market: 192.75 +0.3 (+0.16%)

Fundamental Rating

5

Taking everything into account, ABBV scores 5 out of 10 in our fundamental rating. ABBV was compared to 560 industry peers in the Biotechnology industry. ABBV has an excellent profitability rating, but there are concerns on its financial health. ABBV scores decently on growth, while it is valued quite cheap. This could make an interesting combination. ABBV also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

In the past year ABBV was profitable.
In the past year ABBV had a positive cash flow from operations.
ABBV had positive earnings in each of the past 5 years.
Each year in the past 5 years ABBV had a positive operating cash flow.
ABBV Yearly Net Income VS EBIT VS OCF VS FCFABBV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

Looking at the Return On Assets, with a value of 3.05%, ABBV belongs to the top of the industry, outperforming 91.81% of the companies in the same industry.
ABBV has a Return On Equity of 292.61%. This is amongst the best in the industry. ABBV outperforms 99.82% of its industry peers.
ABBV has a Return On Invested Capital of 13.43%. This is amongst the best in the industry. ABBV outperforms 96.26% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ABBV is in line with the industry average of 14.78%.
Industry RankSector Rank
ROA 3.05%
ROE 292.61%
ROIC 13.43%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.6%
ABBV Yearly ROA, ROE, ROICABBV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

The Profit Margin of ABBV (7.24%) is better than 92.35% of its industry peers.
In the last couple of years the Profit Margin of ABBV has declined.
With an excellent Operating Margin value of 30.43%, ABBV belongs to the best of the industry, outperforming 97.69% of the companies in the same industry.
ABBV's Operating Margin has declined in the last couple of years.
ABBV has a Gross Margin of 70.69%. This is amongst the best in the industry. ABBV outperforms 82.21% of its industry peers.
In the last couple of years the Gross Margin of ABBV has declined.
Industry RankSector Rank
OM 30.43%
PM (TTM) 7.24%
GM 70.69%
OM growth 3Y-5.46%
OM growth 5Y-6.07%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
ABBV Yearly Profit, Operating, Gross MarginsABBV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ABBV is still creating some value.
Compared to 1 year ago, ABBV has about the same amount of shares outstanding.
Compared to 5 years ago, ABBV has more shares outstanding
Compared to 1 year ago, ABBV has a worse debt to assets ratio.
ABBV Yearly Shares OutstandingABBV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ABBV Yearly Total Debt VS Total AssetsABBV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

ABBV has an Altman-Z score of 2.18. This is not the best score and indicates that ABBV is in the grey zone with still only limited risk for bankruptcy at the moment.
ABBV has a Altman-Z score of 2.18. This is in the better half of the industry: ABBV outperforms 71.00% of its industry peers.
ABBV has a debt to FCF ratio of 4.54. This is a neutral value as ABBV would need 4.54 years to pay back of all of its debts.
ABBV has a better Debt to FCF ratio (4.54) than 93.42% of its industry peers.
ABBV has a Debt/Equity ratio of 46.56. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of ABBV (46.56) is worse than 84.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 46.56
Debt/FCF 4.54
Altman-Z 2.18
ROIC/WACC1.42
WACC9.45%
ABBV Yearly LT Debt VS Equity VS FCFABBV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

A Current Ratio of 0.76 indicates that ABBV may have some problems paying its short term obligations.
With a Current ratio value of 0.76, ABBV is not doing good in the industry: 89.50% of the companies in the same industry are doing better.
A Quick Ratio of 0.64 indicates that ABBV may have some problems paying its short term obligations.
ABBV has a Quick ratio of 0.64. This is amonst the worse of the industry: ABBV underperforms 90.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.64
ABBV Yearly Current Assets VS Current LiabilitesABBV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

4

3. Growth

3.1 Past

The earnings per share for ABBV have decreased by -6.30% in the last year.
ABBV shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.51% yearly.
Looking at the last year, ABBV shows a small growth in Revenue. The Revenue has grown by 5.45% in the last year.
Measured over the past years, ABBV shows a quite strong growth in Revenue. The Revenue has been growing by 11.11% on average per year.
EPS 1Y (TTM)-6.3%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%6.49%
Revenue 1Y (TTM)5.45%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%8.39%

3.2 Future

The Earnings Per Share is expected to grow by 13.01% on average over the next years. This is quite good.
ABBV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.55% yearly.
EPS Next Y22.41%
EPS Next 2Y18.82%
EPS Next 3Y16.07%
EPS Next 5Y13.01%
Revenue Next Year6.86%
Revenue Next 2Y7.54%
Revenue Next 3Y7.35%
Revenue Next 5Y6.55%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ABBV Yearly Revenue VS EstimatesABBV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B
ABBV Yearly EPS VS EstimatesABBV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 18.74 indicates a rather expensive valuation of ABBV.
Based on the Price/Earnings ratio, ABBV is valued cheaply inside the industry as 95.55% of the companies are valued more expensively.
ABBV's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.30.
The Price/Forward Earnings ratio is 13.47, which indicates a correct valuation of ABBV.
95.02% of the companies in the same industry are more expensive than ABBV, based on the Price/Forward Earnings ratio.
ABBV's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 21.76.
Industry RankSector Rank
PE 18.74
Fwd PE 13.47
ABBV Price Earnings VS Forward Price EarningsABBV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ABBV indicates a rather cheap valuation: ABBV is cheaper than 95.20% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ABBV indicates a rather cheap valuation: ABBV is cheaper than 94.31% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 22.1
EV/EBITDA 15.62
ABBV Per share dataABBV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of ABBV may justify a higher PE ratio.
A more expensive valuation may be justified as ABBV's earnings are expected to grow with 16.07% in the coming years.
PEG (NY)0.84
PEG (5Y)7.46
EPS Next 2Y18.82%
EPS Next 3Y16.07%

7

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 3.36%, ABBV has a reasonable but not impressive dividend return.
ABBV's Dividend Yield is rather good when compared to the industry average which is at 79.99. ABBV pays more dividend than 99.11% of the companies in the same industry.
ABBV's Dividend Yield is a higher than the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 3.36%

5.2 History

The dividend of ABBV is nicely growing with an annual growth rate of 7.72%!
ABBV has paid a dividend for at least 10 years, which is a reliable track record.
ABBV has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)7.72%
Div Incr Years11
Div Non Decr Years11
ABBV Yearly Dividends per shareABBV Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

ABBV pays out 269.03% of its income as dividend. This is not a sustainable payout ratio.
ABBV's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP269.03%
EPS Next 2Y18.82%
EPS Next 3Y16.07%
ABBV Yearly Income VS Free CF VS DividendABBV Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
ABBV Dividend Payout.ABBV Dividend Payout, showing the Payout Ratio.ABBV Dividend Payout.PayoutRetained Earnings

ABBVIE INC

NYSE:ABBV (7/11/2025, 8:04:00 PM)

After market: 192.75 +0.3 (+0.16%)

192.45

-2.55 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-25 2025-04-25/bmo
Earnings (Next)07-31 2025-07-31/bmo
Inst Owners74.24%
Inst Owner Change0%
Ins Owners0.05%
Ins Owner Change2.83%
Market Cap339.94B
Analysts78.82
Price Target215.89 (12.18%)
Short Float %0.83%
Short Ratio2.09
Dividend
Industry RankSector Rank
Dividend Yield 3.36%
Yearly Dividend6.24
Dividend Growth(5Y)7.72%
DP269.03%
Div Incr Years11
Div Non Decr Years11
Ex-Date07-15 2025-07-15 (1.64)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.58%
Min EPS beat(2)0.02%
Max EPS beat(2)1.14%
EPS beat(4)4
Avg EPS beat(4)0.84%
Min EPS beat(4)0.02%
Max EPS beat(4)1.28%
EPS beat(8)7
Avg EPS beat(8)0.85%
EPS beat(12)8
Avg EPS beat(12)0.35%
EPS beat(16)10
Avg EPS beat(16)0.22%
Revenue beat(2)1
Avg Revenue beat(2)0.51%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)1.23%
Revenue beat(4)2
Avg Revenue beat(4)0.35%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.35%
Revenue beat(12)4
Avg Revenue beat(12)-0.56%
Revenue beat(16)5
Avg Revenue beat(16)-0.82%
PT rev (1m)-0.38%
PT rev (3m)-1.75%
EPS NQ rev (1m)-4.4%
EPS NQ rev (3m)-0.42%
EPS NY rev (1m)-0.87%
EPS NY rev (3m)-1.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.33%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.6%
Valuation
Industry RankSector Rank
PE 18.74
Fwd PE 13.47
P/S 5.93
P/FCF 22.1
P/OCF 20.73
P/B 239.4
P/tB N/A
EV/EBITDA 15.62
EPS(TTM)10.27
EY5.34%
EPS(NY)14.29
Fwd EY7.42%
FCF(TTM)8.71
FCFY4.53%
OCF(TTM)9.28
OCFY4.82%
SpS32.48
BVpS0.8
TBVpS-52.28
PEG (NY)0.84
PEG (5Y)7.46
Profitability
Industry RankSector Rank
ROA 3.05%
ROE 292.61%
ROCE 17.5%
ROIC 13.43%
ROICexc 14.15%
ROICexgc 565.94%
OM 30.43%
PM (TTM) 7.24%
GM 70.69%
FCFM 26.82%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.6%
ROICexc(3y)15.06%
ROICexc(5y)13.83%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.16%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.46%
OM growth 3Y-5.46%
OM growth 5Y-6.07%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score6
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 46.56
Debt/FCF 4.54
Debt/EBITDA 2.56
Cap/Depr 12.17%
Cap/Sales 1.77%
Interest Coverage 250
Cash Conversion 63.55%
Profit Quality 370.28%
Current Ratio 0.76
Quick Ratio 0.64
Altman-Z 2.18
F-Score6
WACC9.45%
ROIC/WACC1.42
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.3%
EPS 3Y-7.24%
EPS 5Y2.51%
EPS Q2Q%6.49%
EPS Next Y22.41%
EPS Next 2Y18.82%
EPS Next 3Y16.07%
EPS Next 5Y13.01%
Revenue 1Y (TTM)5.45%
Revenue growth 3Y0.08%
Revenue growth 5Y11.11%
Sales Q2Q%8.39%
Revenue Next Year6.86%
Revenue Next 2Y7.54%
Revenue Next 3Y7.35%
Revenue Next 5Y6.55%
EBIT growth 1Y9.32%
EBIT growth 3Y-5.38%
EBIT growth 5Y4.37%
EBIT Next Year22.05%
EBIT Next 3Y14.64%
EBIT Next 5Y10.77%
FCF growth 1Y-34.59%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-32.31%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%